INCY News and Press, Incyte Corporation From 04/28/22

Incyte (NASDAQ:INCY) and Maruho Co., Ltd. today announced that the companies have entered into a Strategic Alliance Agreement for the development, manufacturing and exclusive commercialization of ruxolitinib cream, a novel cream formulation of Incyte’s selective JAK2 inhibitor ru...

BBH’s price multiples indicate an undervaluation and its major holdings have started recording significant price growth. BBH has strong fundamentals and has performed well enough in the medium and long term. BBH will face some minor ups and downs since most stocks are yet t...

The positive opinion from the CHMP is based on Phase 2 GEOMETRY mono-1 study showing an overall response rate (ORR) of 51.6% in a cohort evaluating second-line patients only and 44% in all previously-treated patients with advanced non-small cell lung cancer (NSCLC) harboring alterat...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q4-2021 13F filings the consensus holdings were updated, 7 stocks were removed and 7 added from the unive...

Jakafi (ruxolitinib) sales were up 15% y/y and the label is expanding. Olumiant is ramping up royalties. Behind approved drugs is an extensive pipeline to build revenue over this decade. For further details see: Incyte Is A Buy As Ruxolitinib Ramps Revenue And Pipeline M...

Data from a phase 2 trial receiving AbbVie's (NYSE:ABBV) navitoclax in combination with Jakafi (ruxolitinib) found that 12 of 32 evaluable patients (38%) had a ≥1 grade improvement in bone marrow fibrosis at any time point in the study. Patients enrolled in the trial had either progres...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion in Assets Under Management. After the Q4-2021 13F filings the consensus holdings were updated, 7 stocks were removed and 7 added from the un...

Today's $19 share quote is backed by as much as $7.50 in cash vs. total liabilities under $1 per unit. Larger drug trials are underway testing the usefulness of two cancer-related products. Strong technical momentum trends have been building since December. For further detai...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q4-2021 13F filings the consensus holdings were updated, 7 stocks were removed and 7 added from the unive...

Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...